Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer-final results at 20-year follow-up.

Chakrabarti J, Kenny FS, Syed BM, Robertson JF, Blamey RW, Cheung KL.

Crit Rev Oncol Hematol. 2011 Jun;78(3):260-4. doi: 10.1016/j.critrevonc.2010.04.006. Epub 2010 May 5.

PMID:
20447833
2.

Genome remodelling in a basal-like breast cancer metastasis and xenograft.

Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, Kalicki J, Zhang Q, Chen L, Lin L, Wendl MC, McMichael JF, Magrini VJ, Cook L, McGrath SD, Vickery TL, Appelbaum E, Deschryver K, Davies S, Guintoli T, Lin L, Crowder R, Tao Y, Snider JE, Smith SM, Dukes AF, Sanderson GE, Pohl CS, Delehaunty KD, Fronick CC, Pape KA, Reed JS, Robinson JS, Hodges JS, Schierding W, Dees ND, Shen D, Locke DP, Wiechert ME, Eldred JM, Peck JB, Oberkfell BJ, Lolofie JT, Du F, Hawkins AE, O'Laughlin MD, Bernard KE, Cunningham M, Elliott G, Mason MD, Thompson DM Jr, Ivanovich JL, Goodfellow PJ, Perou CM, Weinstock GM, Aft R, Watson M, Ley TJ, Wilson RK, Mardis ER.

Nature. 2010 Apr 15;464(7291):999-1005. doi: 10.1038/nature08989.

3.

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.

Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, RĂ©vil C, Jones A.

J Clin Oncol. 2009 Nov 20;27(33):5529-37. doi: 10.1200/JCO.2008.20.6847. Epub 2009 Sep 28.

PMID:
19786670
4.

Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.

Olson JA Jr, Budd GT, Carey LA, Harris LA, Esserman LJ, Fleming GF, Marcom PK, Leight GS Jr, Giuntoli T, Commean P, Bae K, Luo J, Ellis MJ.

J Am Coll Surg. 2009 May;208(5):906-14; discussion 915-6. doi: 10.1016/j.jamcollsurg.2009.01.035.

5.

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.

J Clin Oncol. 2009 Jun 1;27(16):2630-7. doi: 10.1200/JCO.2008.18.8391. Epub 2009 Apr 20.

PMID:
19380449
6.

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.

Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, Snider J, Davies SR, Olson JA Jr, Watson MA, Saporita A, Weber JD, Ellis MJ.

Cancer Res. 2009 May 1;69(9):3955-62. doi: 10.1158/0008-5472.CAN-08-4450. Epub 2009 Apr 14.

7.

Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.

Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB, Dixon JM.

J Clin Oncol. 2009 Mar 20;27(9):1382-7. doi: 10.1200/JCO.2008.16.8849. Epub 2009 Feb 17.

PMID:
19224856
8.

Supervised risk predictor of breast cancer based on intrinsic subtypes.

Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS.

J Clin Oncol. 2009 Mar 10;27(8):1160-7. doi: 10.1200/JCO.2008.18.1370. Epub 2009 Feb 9.

9.

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.

J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. doi: 10.1093/jnci/djn309. Epub 2008 Sep 23.

10.

Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer.

Seo JH, Kim YH, Kim JS.

Cancer Chemother Pharmacol. 2009 Jan;63(2):261-6. doi: 10.1007/s00280-008-0735-5. Epub 2008 Mar 26.

PMID:
18365197
11.

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).

Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R; Austrian Breast, Colorectal Cancer Study Group (ABCSG).

Breast Cancer Res Treat. 2008 Nov;112(1):203-13. Epub 2007 Dec 22.

PMID:
18158620
12.

HER2 and response to paclitaxel in node-positive breast cancer.

Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA; Cancer and Leukemia Group B (CALGB) Investigators.

N Engl J Med. 2007 Oct 11;357(15):1496-506.

13.

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2007 Oct 1;25(28):4414-22. Epub 2007 Sep 4.

PMID:
17785706
14.

Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.

Torrisi R, Bagnardi V, Pruneri G, Ghisini R, Bottiglieri L, Magni E, Veronesi P, D'Alessandro C, Luini A, Dellapasqua S, Viale G, Goldhirsch A, Colleoni M.

Br J Cancer. 2007 Sep 17;97(6):802-8. Epub 2007 Aug 21.

15.

A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.

Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J, Clark E, Magill P, Dowsett M.

J Clin Oncol. 2007 Sep 1;25(25):3816-22. Epub 2007 Aug 6.

PMID:
17679728
16.

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.

Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A, Berstein LM.

Cancer. 2007 Jul 15;110(2):244-54.

17.

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.

Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G; IMPACT Trialists Group.

J Natl Cancer Inst. 2007 Jan 17;99(2):167-70.

PMID:
17228000
18.

The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.

Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y, Ellis MJ.

Breast Cancer Res Treat. 2007 Mar;102(1):43-9. Epub 2006 Aug 8.

PMID:
16897431
19.

Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.

Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM.

J Clin Oncol. 2006 Jul 1;24(19):3019-25. Epub 2006 Jun 5.

PMID:
16754938
20.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP.

JAMA. 2006 Apr 12;295(14):1658-67. Erratum in: JAMA. 2006 May 24;295(20):2356.

Supplemental Content

Support Center